Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3705 | Zinc Sulfate Wiki | 1.00 |
drug1084 | Doxycycline Wiki | 0.45 |
drug341 | Azithromycin Wiki | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.18 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease. An excessive and counterproductive systemic inflammatory response is thought to be a major cause of severe disease and death in patients with COVID-19. Severe ICU cases frequently have markedly higher levels of inflammatory markers such as CRP, IL-6, IL and TNF-a; which is thought to be correlated with increasing disease severity. The relationship between dysregulated inflammatory processes and disease states such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are well understood. ALI is characterized by an acute exaggerated mononuclear/neutrophilic inflammatory response followed by progressive collagen deposition in the lung, and if severe enough, may progress to ARDS requiring ventilation.
Description: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Interleukin 1-Beta (IL-1B) (pg/mL) Time: Through study completion - up to 12 monthsDescription: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Interleukin 6 (IL-6) (pg/mL) Time: Through study completion - up to 12 monthsDescription: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: C-reactive protein (CRP) (mg/mL) Time: Through study completion - up to 12 monthsDescription: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Tumour Necrosis Factor Alpha (TNFa) (pg/mL) Time: Through study completion - up to 12 monthsDescription: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Neutrophil to Lymphocyte Ratio (NLR) (absolute neutrophils/lymphocytes) Time: Through study completion - up to 12 monthsDescription: Serum concentration, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Serum Ferritin (ng/mL) Time: Through study completion - up to 12 monthsDescription: Standard coagulation parameter, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: International Normalized Ratio (INR) Time: Through study completion - up to 12 monthsDescription: Standard coagulation parameter, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point)
Measure: Prothrombin Time (PTT) Time: Through study completion - up to 12 monthsDescription: ROTEM coagulation assessment using the commercial ROTEM device traditionally used for the assessment of coagulopathy, to be collected immediately before RIC treatment, treatment plus 6 hours, treatment plus 12 hours, treatment plus 24 hours, and treatment plus 48 hours (+/- 1 hour at each 0+ time point).
Measure: Rotational Thromboelastometry (ROTEM) Time: Through study completion - up to 12 monthsDescription: Number of continuous calendar days or partial calendar days including treatment with invasive ventilation.
Measure: Total duration of mechanical ventilation (number of days) Time: Through study completion - up to 12 monthsDescription: Number of continuous calendar days or partial calendar days admitted to an acute care hospital.
Measure: Intensive Care Unit Length of Stay (number of days) Time: Through study completion - up to 12 monthsDescription: Number of continuous calendar days or partial calendar days admitted to an acute care hospital.
Measure: Hospital Length of Stay (number of days) Time: Through study completion - up to 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports